Literature DB >> 17929276

Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.

Carlise R Bethel1, Charles J Bieberich.   

Abstract

BACKGROUND: The transgenic adenocarcinoma of mouse prostate (TRAMP) model has been extensively characterized at the histological and molecular levels, and has been shown to mimic significant features of human prostate cancer. However, the status of Nkx3.1 expression in the TRAMP model has not been elucidated.
METHODS: Immunohistochemical analyses were performed using dorsal, lateral, and ventral prostate (VP) lobes from ages 6 to 30 weeks. Quantitative RT-PCR analyses were performed to determine relative mRNA expression.
RESULTS: Heterogeneous loss of Nkx3.1 was observed in hyperplastic lesions of the ventral, dorsal, and lateral lobes. At 6 weeks of age, the ventral lobe displayed profound loss of Nkx3.1. Diminished Nkx3.1 protein was observed in well- to moderately-differentiated cancer lesions of all lobes. Poorly differentiated (PD) tumors stained negatively for Nkx3.1. Quantitative RT-PCR analyses revealed the presence of Nkx3.1 mRNA in each lobe at all ages, albeit reduced to variable levels.
CONCLUSIONS: These data suggest that disease progression in the TRAMP model may be driven by loss of function of Nkx3.1, in addition to p53 and Rb. Lobe-specific disease progression in the TRAMP model correlates with the reduction of Nkx3.1 protein. Regulation of Nkx3.1 expression during tumorigenesis appears to occur by post-transcriptional and post-translational mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17929276     DOI: 10.1002/pros.20579

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia.

Authors:  May Khalili; Laura N Mutton; Bora Gurel; Jessica L Hicks; Angelo M De Marzo; Charles J Bieberich
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.

Authors:  Raleigh D Kladney; Robert D Cardiff; David J Kwiatkowski; Gary G Chiang; Jason D Weber; Jeffrey M Arbeit; Zhi Hong Lu
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

3.  Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Authors:  H Song; B Zhang; M A Watson; P A Humphrey; H Lim; J Milbrandt
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

4.  Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1.

Authors:  Varsha Rao; Bin Guan; Laura N Mutton; Charles J Bieberich
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

5.  Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.

Authors:  Sanjeev Shukla; Natarajan Bhaskaran; Gregory T Maclennan; Sanjay Gupta
Journal:  Prostate       Date:  2013-06-13       Impact factor: 4.104

6.  Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.

Authors:  Heyu Zhang; Michael H Muders; Jinping Li; Francesca Rinaldo; Donald J Tindall; Kaustubh Datta
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

7.  Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3' genomic region.

Authors:  Qing Xie; Zhu A Wang
Journal:  J Biol Chem       Date:  2017-07-05       Impact factor: 5.157

Review 8.  Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.

Authors:  Cory Abate-Shen; Michael M Shen; Edward Gelmann
Journal:  Differentiation       Date:  2008-06-28       Impact factor: 3.880

9.  SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Authors:  Murali Gururajan; Karen A Cavassani; Margarit Sievert; Peng Duan; Jake Lichterman; Jen-Ming Huang; Bethany Smith; Sungyong You; Srinivas Nandana; Gina Chia-Yi Chu; Sheldon Mink; Sajni Josson; Chunyan Liu; Matteo Morello; Lawrence W M Jones; Jayoung Kim; Michael R Freeman; Neil Bhowmick; Haiyen E Zhau; Leland W K Chung; Edwin M Posadas
Journal:  Oncotarget       Date:  2015-12-29

Review 10.  Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

Authors:  Richard J Rebello; Richard B Pearson; Ross D Hannan; Luc Furic
Journal:  Genes (Basel)       Date:  2017-02-16       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.